Immunome Statistics
Total Valuation
Immunome has a market cap or net worth of $763.10 million. The enterprise value is $450.55 million.
Important Dates
The next estimated earnings date is Monday, August 11, 2025, after market close.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunome has 87.01 million shares outstanding. The number of shares has increased by 121.01% in one year.
| Current Share Class | 87.01M |
| Shares Outstanding | 87.01M |
| Shares Change (YoY) | +121.01% |
| Shares Change (QoQ) | +26.37% |
| Owned by Insiders (%) | 3.47% |
| Owned by Institutions (%) | 76.92% |
| Float | 69.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 52.96 |
| Forward PS | n/a |
| PB Ratio | 2.50 |
| P/TBV Ratio | 2.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 41.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.49, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.49 |
| Quick Ratio | 10.30 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -69.21% and return on invested capital (ROIC) is -37.09%.
| Return on Equity (ROE) | -69.21% |
| Return on Assets (ROA) | -33.54% |
| Return on Invested Capital (ROIC) | -37.09% |
| Return on Capital Employed (ROCE) | -56.99% |
| Revenue Per Employee | $92,695 |
| Profits Per Employee | -$1.74M |
| Employee Count | 118 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.10% in the last 52 weeks. The beta is 1.95, so Immunome's price volatility has been higher than the market average.
| Beta (5Y) | 1.95 |
| 52-Week Price Change | -27.10% |
| 50-Day Moving Average | 8.56 |
| 200-Day Moving Average | 10.36 |
| Relative Strength Index (RSI) | 48.90 |
| Average Volume (20 Days) | 828,543 |
Short Selling Information
The latest short interest is 12.52 million, so 14.39% of the outstanding shares have been sold short.
| Short Interest | 12.52M |
| Short Previous Month | 13.24M |
| Short % of Shares Out | 14.39% |
| Short % of Float | 18.01% |
| Short Ratio (days to cover) | 13.74 |
Income Statement
In the last 12 months, Immunome had revenue of $10.94 million and -$205.11 million in losses. Loss per share was -$3.13.
| Revenue | 10.94M |
| Gross Profit | -140.11M |
| Operating Income | -177.75M |
| Pretax Income | -232.03M |
| Net Income | -205.11M |
| EBITDA | -175.73M |
| EBIT | -177.75M |
| Loss Per Share | -$3.13 |
Full Income StatementBalance Sheet
The company has $317.32 million in cash and $4.77 million in debt, giving a net cash position of $312.55 million or $3.59 per share.
| Cash & Cash Equivalents | 317.32M |
| Total Debt | 4.77M |
| Net Cash | 312.55M |
| Net Cash Per Share | $3.59 |
| Equity (Book Value) | 307.13M |
| Book Value Per Share | 3.53 |
| Working Capital | 292.33M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$152.68 million and capital expenditures -$55.01 million, giving a free cash flow of -$207.69 million.
| Operating Cash Flow | -152.68M |
| Capital Expenditures | -55.01M |
| Free Cash Flow | -207.69M |
| FCF Per Share | -$2.39 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,625.04% |
| Pretax Margin | -1,875.21% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunome does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -121.01% |
| Shareholder Yield | -121.01% |
| Earnings Yield | -26.88% |
| FCF Yield | -27.22% |
Analyst Forecast
The average price target for Immunome is $26.40, which is 201.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $26.40 |
| Price Target Difference | 201.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 89.50% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Immunome has an Altman Z-Score of 10.84 and a Piotroski F-Score of 2.
| Altman Z-Score | 10.84 |
| Piotroski F-Score | 2 |